Skip to main content
Skip to main navigation
Invalid credentials.
Search for :
Product Development Strategy
Early Clinical Development
Phase I/IIa Clinical Trials
Phase II/III Clinical Trials
Interventional Phase IIIb/Phase IV Clinical Trials
Observational Research & Registries
Product Launch & Management
Market Access Solutions
Strategic Sales Outsourcing
Biopharmaceutical R&D
Biopharmaceutical Sales & Marketing
Biosimilars
Healthcare Payers & Providers
Medical Device & Diagnostics
Public Health & Government
Cardiovascular
Central Nervous System
Diabetes & Endocrinology
Infectious Diseases
Internal Medicine
Oncology
Early Phase Oncology
Translational Oncology
Pediatrics
Public Health Interest
Vaccines
Other Therapeutic Areas
Our Focus
Our Values
Our Heritage
Our Perspectives
Our Leadership
Ethics & Compliance
Investors
Merck Serono and Quintiles Announce Innovative Clinical Development Partnership
RESEARCH TRIANGLE PARK, NC – May 15, 2013 – Merck Serono, a division of Merck, Darmstadt, Germany, and Quintiles, the world’s largest provider of biopharmaceutical development and commercial outsourcing services, today announced a new, five-year clinical development agreement.
Read Press ReleaseView All Press Releases
Get updates on News, Events, Presentations and Broadcasts sent to via text or your personal email. You can also subscribe to our podcasts on iTunes to hear the latest broadcasts.
Quintiles Announces Completion of Initial Public Offering of 27,236,841 Shares of Common Stock
Quintiles Announces Pricing of Initial Public Offering
The work we do with the biopharmaceutical industry, payers and providers has a profound effect on extending patients’ lives and quality of life around the world. Learn More About Quintiles